[go: up one dir, main page]

TN2009000110A1 - High affinity human antibodies to human il - 4 receptor - Google Patents

High affinity human antibodies to human il - 4 receptor

Info

Publication number
TN2009000110A1
TN2009000110A1 TN2009000110A TN2009000110A TN2009000110A1 TN 2009000110 A1 TN2009000110 A1 TN 2009000110A1 TN 2009000110 A TN2009000110 A TN 2009000110A TN 2009000110 A TN2009000110 A TN 2009000110A TN 2009000110 A1 TN2009000110 A1 TN 2009000110A1
Authority
TN
Tunisia
Prior art keywords
human
receptor
high affinity
antibodies
human antibodies
Prior art date
Application number
TN2009000110A
Other languages
English (en)
Inventor
Marcela Torres
Kevin J Pobursky
Raymond W Leidich
Joan A Windsor
Warren R Mikulka
Diana M Ahrens
Ergang Shi
Nicholas J Papadopoulos
Sean Stevens
Tammy T Huang
Joel H Martin
Jeanette L Fairhurst
A Rafique
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of TN2009000110A1 publication Critical patent/TN2009000110A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
TN2009000110A 2006-10-02 2009-03-31 High affinity human antibodies to human il - 4 receptor TN2009000110A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84869406P 2006-10-02 2006-10-02
US95773807P 2007-08-24 2007-08-24
PCT/US2007/021210 WO2008054606A2 (fr) 2006-10-02 2007-10-02 Anticorps humains à haute affinité vis-à-vis du récepteur il-4 humain

Publications (1)

Publication Number Publication Date
TN2009000110A1 true TN2009000110A1 (en) 2010-08-19

Family

ID=39344836

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000110A TN2009000110A1 (en) 2006-10-02 2009-03-31 High affinity human antibodies to human il - 4 receptor

Country Status (34)

Country Link
US (4) US7605237B2 (fr)
EP (3) EP3845563A3 (fr)
JP (1) JP2010505418A (fr)
KR (1) KR101474227B1 (fr)
CN (1) CN101522716B (fr)
AU (1) AU2007314522C9 (fr)
BR (1) BRPI0719953B8 (fr)
CA (1) CA2664343C (fr)
CO (1) CO6160305A2 (fr)
CR (1) CR10689A (fr)
CY (1) CY1115551T1 (fr)
DK (2) DK2769992T3 (fr)
DO (1) DOP2009000058A (fr)
ES (2) ES2466669T3 (fr)
HR (2) HRP20140512T1 (fr)
HU (1) HUE054090T2 (fr)
IL (1) IL197479A (fr)
LT (1) LT2769992T (fr)
MA (1) MA31138B1 (fr)
ME (1) ME00616B (fr)
MX (1) MX2009003393A (fr)
MY (1) MY149079A (fr)
NI (1) NI200900041A (fr)
NO (1) NO347180B1 (fr)
NZ (1) NZ576040A (fr)
PL (2) PL2069403T3 (fr)
PT (2) PT2069403E (fr)
RS (2) RS53340B (fr)
RU (1) RU2445318C2 (fr)
SI (2) SI2069403T1 (fr)
TN (1) TN2009000110A1 (fr)
UA (1) UA98943C2 (fr)
WO (1) WO2008054606A2 (fr)
ZA (1) ZA200901617B (fr)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2872136C (fr) 2002-07-18 2017-06-20 Merus B.V. Production par recombinaison de melanges d'anticorps
EP1639009B1 (fr) 2003-05-30 2013-02-27 Merus B.V. Bibliothèque de fragments fab pour préparer un mélange d'anticorps
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2708871C (fr) 2007-12-21 2017-11-21 Medimmune Limited Elements liants destines au recepteur alpha de l'interleukin-4(il-4r-.alpha.) - 173
EP3456190B1 (fr) 2008-06-27 2021-11-24 Merus N.V. Animal murin transgéniques produisant un anticorps
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CN102216327A (zh) * 2008-07-25 2011-10-12 生物医学研究所 中和抗甲型流感病毒抗体及其用途
AU2014216019B2 (en) * 2008-10-29 2016-04-21 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK2798950T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
RS54367B2 (sr) 2010-02-08 2021-08-31 Regeneron Pharma Miš sa zajedničkim lakim lancem
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
LT2905338T (lt) 2010-06-22 2017-12-27 Regeneron Pharmaceuticals, Inc. Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu
RU2612903C2 (ru) * 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
BR112013008366B1 (pt) 2010-10-06 2022-02-08 Regeneron Pharmaceuticals, Inc Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
CA2837169C (fr) 2011-05-24 2021-11-09 Zyngenia, Inc. Complexes multispecifiques contenant un peptide de liaison de l'angiopoietin-2 et utilisations connexes
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
TR201807040T4 (tr) 2011-07-11 2018-06-21 Glenmark Pharmaceuticals Sa Ox40 a bağlanan antikorlar ve bunların kullanımları.
JP6035332B2 (ja) 2011-07-18 2016-11-30 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
JP6510234B2 (ja) 2011-08-05 2019-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ユニバーサル軽鎖マウス
WO2013039969A1 (fr) 2011-09-16 2013-03-21 Regeneron Pharmaceuticals, Inc. Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9)
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
EP2761008A1 (fr) 2011-09-26 2014-08-06 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA2859408C (fr) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Souris a chaines legeres humanisees
CN107361011B (zh) 2012-03-16 2021-08-27 瑞泽恩制药公司 制备表达ph敏感性免疫球蛋白序列的非人动物的方法
PL2883449T3 (pl) 2012-03-16 2018-07-31 Regeneron Pharmaceuticals, Inc. Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane gryzonie do wytwarzania tych przeciwciał
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR102269650B1 (ko) 2012-04-20 2021-06-28 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
PT4011915T (pt) 2012-08-21 2024-01-02 Regeneron Pharma Métodos para o tratamento ou prevenção da asma através da administração de um antagonista de il-4r
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
EP3896088B1 (fr) 2013-02-20 2025-07-23 Innate Pharma Traitement de lymphome t périphérique
DK2840892T3 (en) * 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
CA2907181C (fr) 2013-03-15 2023-10-17 Viktor Roschke Complexes multispecifiques multivalents et monovalents et leurs utilisations
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN105517570B (zh) 2013-06-21 2020-04-07 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CN105683365A (zh) 2013-10-01 2016-06-15 科马布有限公司 动物模型及治疗分子
SG10202103140XA (en) 2013-10-02 2021-05-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CA2939572A1 (fr) * 2014-02-19 2015-08-27 Jody Berry Anticorps monoclonaux de marburg
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP4353254A3 (fr) 2014-02-28 2024-07-03 Regeneron Pharmaceuticals, Inc. Méthodes de traitement d'une infection cutanée par administration d'un antagoniste d'il-4r
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
WO2016011035A2 (fr) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralisation d'anticorps anti-grippe b et leurs utilisations
WO2016023916A1 (fr) 2014-08-12 2016-02-18 Kymab Limited Traitement de maladie par la liaison d'un ligand à des cibles présentant un intérêt
WO2016071701A1 (fr) 2014-11-07 2016-05-12 Kymab Limited Traitement de maladie par liaison de ligand à des cibles d'intérêt
WO2016077675A1 (fr) 2014-11-14 2016-05-19 Sanofi Biotechnology Méthodes de traitement de la sinusite chronique avec polypose nasale par administration d'un antagoniste d'il-4r
JP2018510150A (ja) * 2015-03-06 2018-04-12 ソレント・セラピューティクス・インコーポレイテッド Ｊａｇ１に結合する抗体医薬
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
WO2016161010A2 (fr) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Régions constantes de chaînes lourdes présentant une liaison réduite aux récepteurs fc gamma
CN107683291B (zh) 2015-04-02 2021-11-19 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
JP6867306B2 (ja) 2015-06-01 2021-04-28 メディミューン，エルエルシー 中和抗インフルエンザ結合分子及びその使用
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
TWI797060B (zh) * 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
CN108697789A (zh) 2016-01-13 2018-10-23 免疫医疗有限责任公司 治疗甲型流感的方法
US10314904B2 (en) 2016-02-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
CN109963577B (zh) 2016-09-22 2024-03-12 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
US20190240316A1 (en) * 2016-10-17 2019-08-08 Vanderbilt University Human respiratory syncytial virus antibodies and methods of use therefor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
CA3047115A1 (fr) * 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anticorps anti-proteine 1 contenant un domaine anti-cub (cdcp1), conjugues anticorps-medicament et leurs methodes d'utilisation
IL314591A (en) 2017-04-13 2024-09-01 Regeneron Pharma Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CN107216388B (zh) * 2017-08-07 2020-05-05 广州泰诺迪生物科技有限公司 一种治疗丙型肝炎病毒药物的制备方法和用途
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
CN108373505B (zh) 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
KR20210010518A (ko) 2018-05-13 2021-01-27 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
CA3098040A1 (fr) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Modeles animaux non humains de maladie ditra et leurs utilisations
MX2021001143A (es) 2018-08-24 2021-04-12 Jiangsu Hengrui Medicine Co Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
EP3878868B1 (fr) * 2018-11-09 2024-10-09 Ajou University Industry-Academic Cooperation Foundation Anticorps humain présentant une affinité élevée vis-à-vis du récepteur alpha d'il-4 humain, et son utilisation
CN111514292B (zh) 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
JP7548924B2 (ja) 2019-03-06 2024-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
SG11202108759SA (en) * 2019-04-08 2021-10-28 Phanes Therapeutics Inc Humanized anti-dll3 chimeric antigen receptors and uses thereof
CN111592597B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
AU2020315369A1 (en) 2019-07-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
CN112279914A (zh) * 2019-07-25 2021-01-29 苏州丁孚靶点生物技术有限公司 Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
BR112022000581A2 (pt) 2019-08-05 2022-03-03 Regeneron Pharma Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
BR112022000377A2 (pt) 2019-08-05 2022-05-10 Regeneron Pharma Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r
EP4073810A1 (fr) 2019-12-09 2022-10-19 Sanofi Biotechnology Méthodes de traitement de troubles associés à l'il-4/il-13 identifiés numériquement
EP3992974A1 (fr) 2020-11-02 2022-05-04 Sanofi Biotechnology Procédés pour le traitement de troubles liés à l'il-13/il-4 identifiés numériquement
WO2021167952A2 (fr) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Anticorps agonistes dirigés contre l'endogline (eng) et leurs utilisations
MX2022010217A (es) 2020-02-21 2022-09-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene anticuerpo anti-il-4r y uso de la misma.
EP4110816A1 (fr) * 2020-02-27 2023-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anticorps se liant à il4r et leurs utilisations
JP2023520676A (ja) 2020-03-27 2023-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法
WO2021207709A1 (fr) * 2020-04-10 2021-10-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Liants et récepteurs antigéniques chimériques spécifiques de la protéine accessoire du récepteur de l'interleukine-1
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
EP4183803A4 (fr) 2020-07-17 2024-04-17 GI Innovation, Inc. Protéine de fusion comprenant un domaine extracellulaire de sous-unité alpha du récepteur fc d'ige et un anticorps anti-il-4r, et utilisation associée
KR102697769B1 (ko) 2020-09-14 2024-08-23 아주대학교산학협력단 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
JP2023544406A (ja) 2020-10-05 2023-10-23 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法
TW202231663A (zh) 2020-12-22 2022-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ－４ｒ抗體或其抗原結合片段的複合物及醫藥用途
EP4274854A4 (fr) 2021-01-08 2025-03-26 Bristol-Myers Squibb Company Anticorps et peptides de liaison à l'antigène pour des inhibiteurs du facteur xia et leurs utilisations
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
CA3226781A1 (fr) 2021-07-26 2023-02-02 Nikhil AMIN Methodes de traitement de l'urticaire spontanee chronique par administration d'un antagoniste de l'il-4r
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
WO2023028468A1 (fr) 2021-08-23 2023-03-02 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de la dermatite atopique par administration d'un antagoniste d'il-4r
CN119174816A (zh) * 2021-08-26 2024-12-24 正大天晴药业集团股份有限公司 抗il4r抗体的药物组合物及其用途
IL312187A (en) 2021-10-20 2024-06-01 Regeneron Pharma Methods for treating prurigo nodularis by administering an IL-4R antagonist
CN118355034A (zh) 2021-12-30 2024-07-16 瑞泽恩制药公司 施用il-4/il-13拮抗剂以减弱特应性进程的方法
MX2024009080A (es) 2022-01-29 2024-07-30 Shanghai Shengdi Pharmaceutical Co Ltd Conjugado farmacologico de glucocorticoide.
AU2023227209A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
KR20250004863A (ko) 2022-05-02 2025-01-08 리제너론 파아마슈티컬스, 인크. 항-인터류킨-4 수용체(il-4r) 항체 제형
IL316694A (en) 2022-05-02 2024-12-01 Regeneron Pharma Methods for reducing lipase activity
TW202421660A (zh) 2022-07-08 2024-06-01 美商再生元醫藥公司 藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法
JP2025528456A (ja) 2022-08-29 2025-08-28 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストの投与による慢性誘発性寒冷蕁麻疹の治療方法
KR20250096792A (ko) 2022-11-01 2025-06-27 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여하여 손 및 발 피부염을 치료하기 위한 방법
IL320670A (en) 2022-11-23 2025-07-01 Regeneron Pharma Methods for enhancing bone growth by administering an IL-4R antagonist
US20240360232A1 (en) 2023-03-22 2024-10-31 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
CN121001741A (zh) 2023-03-27 2025-11-21 瑞泽恩制药公司 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
WO2025075970A1 (fr) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Système de sécurité pour dispositif d'administration de médicament
WO2025096932A1 (fr) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Procédés pour réduire l'activité de lipase à l'aide d'une contrainte
WO2025137344A1 (fr) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Anticorps ciblant le récepteur bêta de l'il-18 (il-18rβ) et procédés associés
WO2025221640A1 (fr) 2024-04-15 2025-10-23 Sanofi Biotechnology Méthodes de traitement de la rhinosinusite chronique sans polypes nasaux par administration d'un antagoniste d'il-4r

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US809A (en) 1838-06-27 Improved mode of changing the poles of electro-magnets
US7186A (en) 1850-03-19 fetchec
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) * 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (fr) * 1992-12-29 1994-07-06 Schering-Plough Anticorps monoclonaux contre le récepteur de l'interleukine-4 humain et hydridomes les produisant
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2292665B1 (fr) * 2000-05-26 2015-07-08 Immunex Corporation Utilisation des anticorps de l'interleukine-4 et compositions correspondantes
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1461300T3 (da) * 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
NZ547588A (en) * 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
ATE395358T1 (de) * 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
US8338135B2 (en) 2012-12-25
SI2769992T1 (sl) 2021-04-30
CR10689A (es) 2009-06-24
WO2008054606A3 (fr) 2009-02-05
NI200900041A (es) 2011-10-17
NZ576040A (en) 2011-06-30
RU2445318C2 (ru) 2012-03-20
DK2769992T3 (da) 2021-03-22
CN101522716A (zh) 2009-09-02
SI2069403T1 (sl) 2014-09-30
MEP11109A (en) 2011-12-20
AU2007314522A1 (en) 2008-05-08
UA98943C2 (ru) 2012-07-10
US7605237B2 (en) 2009-10-20
ZA200901617B (en) 2009-12-30
MX2009003393A (es) 2009-05-11
HK1200846A1 (en) 2015-08-14
HRP20140512T1 (hr) 2014-07-04
EP2069403A2 (fr) 2009-06-17
RS53340B (sr) 2014-10-31
AU2007314522C9 (en) 2013-08-01
AU2007314522A8 (en) 2013-04-11
EP2069403B1 (fr) 2014-05-07
NO347180B1 (no) 2023-06-19
AU2007314522C1 (en) 2013-06-27
HK1131790A1 (en) 2010-02-05
ES2466669T3 (es) 2014-06-10
IL197479A0 (en) 2011-08-01
AU2007314522B2 (en) 2013-02-21
ES2859825T3 (es) 2021-10-04
EP2769992B1 (fr) 2020-12-30
CO6160305A2 (es) 2010-05-20
LT2769992T (lt) 2021-04-12
PT2069403E (pt) 2014-07-18
EP3845563A2 (fr) 2021-07-07
EP2769992A3 (fr) 2015-01-21
RU2009116608A (ru) 2010-11-10
BRPI0719953A2 (pt) 2014-04-29
NO20091758L (no) 2009-05-04
HRP20210408T1 (hr) 2021-04-30
PL2769992T3 (pl) 2021-08-02
US20100021476A1 (en) 2010-01-28
US20080160035A1 (en) 2008-07-03
MY149079A (en) 2013-07-15
AU2007314522A2 (en) 2009-07-02
EP2769992A2 (fr) 2014-08-27
CA2664343C (fr) 2016-04-26
CY1115551T1 (el) 2017-01-04
US20100291107A1 (en) 2010-11-18
JP2010505418A (ja) 2010-02-25
US7794717B2 (en) 2010-09-14
PL2069403T3 (pl) 2015-08-31
BRPI0719953B8 (pt) 2021-05-25
KR20090088865A (ko) 2009-08-20
WO2008054606A2 (fr) 2008-05-08
DK2069403T3 (da) 2014-07-28
PT2769992T (pt) 2021-03-11
MA31138B1 (fr) 2010-02-01
EP3845563A3 (fr) 2021-11-24
RS61650B1 (sr) 2021-04-29
CN101522716B (zh) 2013-03-20
KR101474227B1 (ko) 2014-12-18
IL197479A (en) 2014-03-31
HUE054090T2 (hu) 2021-08-30
US8092802B2 (en) 2012-01-10
BRPI0719953B1 (pt) 2019-04-24
ME00616B (me) 2011-12-20
AU2007314522B8 (en) 2013-04-11
CA2664343A1 (fr) 2008-05-08
DOP2009000058A (es) 2009-04-30
US20120135010A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
TN2009000110A1 (en) High affinity human antibodies to human il - 4 receptor
EP4345111A3 (fr) Anticorps humains à haute affinité pour le récepteur il-4 humain
SV2009003296A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
WO2012175222A8 (fr) Immunocytokines à base d'il-15 et domaine sushi d'il-15rα
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2010022924A8 (fr) Anticorps contre le récepteur de l'epo humaine
TN2011000133A1 (en) High affinity human antibodies to human il-4 receptor
HN2009000575A (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano